





ICH, CVD, and ICAD  
Roundtable Discussion  
with Industry and  
Stroke Experts

05/23-24  
2024

WASHINGTON DC, USA



EXPANDING THE SCOPE OF  
INTRACRANIAL HEMORRHAGE  
(ICH), CEREBRAL VENOUS  
DISEASE (CVD) AND  
INTRACRANIAL  
ATHEROOCCLUSIVE DISEASE  
(ICAD) TREATMENT

New Perspectives on Epidemiology, Clinical  
Trials, Patient Selection, Evolving Therapies  
and Pre-clinical System Models





## MISSION:

The ARISE Consensus Conferences, via a collaboration of medical academia, the healthcare industry and government agencies, are intended to advance and accelerate research in the treatment of intracranial hemorrhage (ICH), intracranial atherosclerotic disease (ICAD), and cerebral venous diseases (CVD), to ultimately result in improved acute and elective management, treatment, and prevention. To achieve this goal, **ARISE 2024 will:**

- ✚ *Develop new approaches to overcome barriers impeding drug and device development*
- ✚ *Identify, clarify, and communicate the implications of new research for cerebrovascular diseases*
- ✚ *Publish the consensus recommendations of ARISE participants which address these concerns*
- ✚ *Promote adoption of ARISE solutions by research, industry, clinical and government communities*

## WHO IS INVOLVED:

ARISE architecture thus includes **3 major stakeholders research and practice in the treatment of cerebrovascular disease: academia** (leading international physicians/scientists from all involved disciplines), **industry** (scientists and executives from private sector pharmaceutical, device, and imaging companies), and **regulatory institutions** (executive managers, physicians and scientists from NIH and FDA).


## PRELIMINARY AGENDA:

ARISE starts with a **one full day** meeting focusing on cutting-edge clinical and research study designs, analytic methods, novel drugs/devices, biomarkers, and outcomes. The specific sessions included in the program are:

- ✚ **SESSION 1:** Intracerebral hemorrhage (ICH) – NEW DATA, NEW LANDSCAPE, NEW APPROACHES
- ✚ **SESSION 2:** Cerebral Venous Diseases: NEW DATA, NEW LANDSCAPE, NEW APPROACHES
- ✚ **SESSION 3:** Intracranial Atheroocclusive Disease (ICAD): NEW DATA, NEW LANDSCAPE, NEW APPROACHES
- ✚ **SESSION 4:** REGULATORY PERSPECTIVE ON KEY CLINICAL TRIAL ISSUES

The **second day** of the ARISE is focused on the consensus process to develop recommendations. Participating experts from academia, industry and regulatory institutions are divided into 3 groups for preparation of the consensus recommendations. They are provided equal opportunity to contribute to a facilitated discussion process, during which recommendations developed by leading academic thought leaders in ICH, ICAD, and CVD are presented, openly discussed, and may be amended, expanded, replaced, and refined by the group. Each of the 3 content groups then present their recommendations to the entire assembly. Writing committees draft the manuscripts for review of the group and the resulting articles are then published.






## SECOND DAY WORKSHOPS:

- WORKSHOP 1:** MOST PROMISING APPROACHES TO IMPROVE VENOPATHY OUTCOMES  
**Facilitators – Co-Chairs:** Vitor Pereira, Felipe Albuquerque, Matthew Amans
- WORKSHOP 2:** MOST PROMISING APPROACHES TO IMPROVE INTRACEREBRAL HEMORRHAGE  
**Facilitators – Co-Chairs:** Mark Bain, Christopher Kellner, Ricardo Hanel
- WORKSHOP 3:** MOST PROMISING APPROACHES TO IMPROVE INTRACRANIAL ATHEROOCCLUSIVE DISEASE OUTCOMES  
**Facilitators – Co-Chairs:** Brian Hoh, Stav Tjoumakaris, Guilherme Dabus

## CORE ORGANISERS:



**Prof Ajay K. Wakhloo, MD PhD FAHA FSNIS**  
Professor, TUFTS University School of Medicine,  
Boston, MA



**Prof Adam S. Arthur, MD MPH FAANS FSNIS**  
Professor and chair of Neurosurgery at University of  
Tennessee Health Science Center (UTHSC), Memphis, TN

## INVITATION:

ARISE is a Roundtable where only invited faculty and companies can participate. The goal is to have companies from different fields involved. ARISE is then *inviting* your company to participate in this meeting by supporting this excellent platform that has a goal to foster consensus in areas of major relevance to ARISE and the networks needed to design/conduct successful trials in the field.

*You have the possibility to bring your company's representatives, according to your support level. Please contact us to discuss the possibilities.*

## FOR FURTHER DETAILS, PLEASE CONTACT ME:



**MARIETA TSENEVA**

Industry Liaison & Sales Associate

E: [mtseneva@kenes.com](mailto:mtseneva@kenes.com) | T: +41 22 908 0488 Ext. 273

***Please note, ARISE does not receive any government funding. ARISE conferences are funded solely by participating private sector companies.***

